Jiangsu Recbio Technology (G93) Stock Overview
A vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
G93 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Jiangsu Recbio Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.55 |
| 52 Week High | HK$0.88 |
| 52 Week Low | HK$0.064 |
| Beta | 0.080 |
| 1 Month Change | 7.84% |
| 3 Month Change | 2.80% |
| 1 Year Change | -35.29% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -46.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| G93 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.9% | -0.1% | 0.1% |
| 1Y | -35.3% | 11.4% | -0.5% |
Return vs Industry: G93 underperformed the German Biotechs industry which returned 11.4% over the past year.
Return vs Market: G93 underperformed the German Market which returned -0.5% over the past year.
Price Volatility
| G93 volatility | |
|---|---|
| G93 Average Weekly Movement | 17.2% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: G93's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: G93's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 491 | Yong Liu | www.recbio.cn |
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601, a recombinant HPV bivalent vaccines targeting HPV type 16/18 that is in phase I clinical trial; REC602, recombinant HPV bivalent vaccines targeting HPV type 6/11, which is in phase I clinical trials; REC604a, a novel adjuvanted recombinant HPV quadrivalent vaccine; and REC604c, a recombinant HPV 9-valent vaccine. It also develops REC610, a recombinant shingles vaccine that is in Phase l clinical trial; REC625, a bivalent recombinant respiratory syncytial virus vaccine and REC627, a recombinant metapneumovirus vaccine for the treatment of respiratory diseases caused by respiratory syncytial virus; REC609, a recombinant human cytomegalovirus vaccine for the treatment of human cytomegalovirus disease; and ReCOV, a recombinant bicomponent COVID-19 vaccine candidate that completed phase III clinical trial.
Jiangsu Recbio Technology Co., Ltd. Fundamentals Summary
| G93 fundamental statistics | |
|---|---|
| Market cap | €348.46m |
| Earnings (TTM) | -€79.24m |
| Revenue (TTM) | €1.65m |
Is G93 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G93 income statement (TTM) | |
|---|---|
| Revenue | CN¥12.73m |
| Cost of Revenue | CN¥3.49m |
| Gross Profit | CN¥9.24m |
| Other Expenses | CN¥619.63m |
| Earnings | -CN¥610.39m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.99 |
| Gross Margin | 72.62% |
| Net Profit Margin | -4,796.40% |
| Debt/Equity Ratio | 87.8% |
How did G93 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/23 03:19 |
| End of Day Share Price | 2026/07/23 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jiangsu Recbio Technology Co., Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | CMB International Securities Limited |
| Sean Wu | Morgan Stanley |
| Youjue Hu | Morgan Stanley |